Moderna (NASDAQ:MRNA) Trading 8.8% Higher - What's Next?

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) shot up 8.8% during trading on Tuesday . The company traded as high as $35.00 and last traded at $35.90. 3,115,410 shares were traded during mid-day trading, a decline of 75% from the average session volume of 12,516,600 shares. The stock had previously closed at $32.99.

Analysts Set New Price Targets

A number of brokerages have commented on MRNA. Royal Bank of Canada restated a "sector perform" rating and issued a $40.00 target price on shares of Moderna in a research note on Tuesday. Leerink Partners dropped their target price on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Wolfe Research began coverage on shares of Moderna in a report on Friday, November 15th. They issued an "underperform" rating and a $40.00 price target for the company. The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Finally, Evercore ISI reduced their price objective on shares of Moderna from $60.00 to $50.00 and set an "in-line" rating for the company in a research note on Monday, January 27th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $60.63.

Moderna Price Performance

The business's fifty day moving average price is $38.17 and its two-hundred day moving average price is $53.20. The stock has a market capitalization of $13.67 billion, a PE ratio of -3.83 and a beta of 1.59.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB raised its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the last quarter. Compass Planning Associates Inc acquired a new stake in Moderna during the fourth quarter worth about $37,000. Venturi Wealth Management LLC raised its position in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after acquiring an additional 664 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in Moderna in the fourth quarter valued at approximately $41,000. Finally, Itau Unibanco Holding S.A. boosted its position in Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.